Kinnate Biopharma has been granted a patent for inhibitors of MET receptor tyrosine kinase, which can be used for the treatment of various diseases. The patent includes a specific compound with a defined chemical structure. GlobalData’s report on Kinnate Biopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Kinnate Biopharma Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Kinnate Biopharma, Targeted cancer therapy was a key innovation area identified from patents. Kinnate Biopharma's grant share as of September 2023 was 11%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11753395B2) discloses a compound and its pharmaceutically acceptable forms that have a specific chemical structure. The compound, or its salt or solvate, is represented by Formula (II). The patent claims cover various substitutions for the alkyl and cycloalkyl groups in the compound.

The compound of claim 1 can have R1 as optionally substituted C1-C6 alkyl or optionally substituted C3-C6 cycloalkyl, and R as optionally substituted C1-C6 alkyl or optionally substituted C3-C6 cycloalkyl. The patent also includes claims specifying different substitution options for R1 and R, such as R1 being optionally substituted C3-C6 cycloalkyl or optionally substituted C1-C6 alkyl. Additionally, the claims cover variations where R1 is optionally substituted C1-C2 alkyl or optionally substituted C1 alkyl, and R is optionally substituted C1-C6 alkyl or optionally substituted C1-C4 alkyl.

Furthermore, the patent claims encompass different possibilities for R9, which can be optionally substituted C1-C6 alkyl or optionally substituted C3-C6 cycloalkyl. Specific claims include R9 being optionally substituted C1-C4 alkyl, optionally substituted C1 alkyl, CH3, optionally substituted C3-C6 cycloalkyl, or cyclopropyl.

Other claims in the patent specify that R11 can be hydrogen, R8 can be fluoro or hydrogen, and R6 can be hydrogen or fluoro. The patent also includes claims that combine different substitutions for R9 and R6, such as R9 being optionally substituted C1-C6 alkyl or optionally substituted C3-C6 cycloalkyl, and R6 being fluoro.

In addition to the compound itself, the patent covers a pharmaceutical composition comprising the compound (or its salt or solvate) described in claim 1 and a pharmaceutically acceptable excipient. This composition can be used for various pharmaceutical applications.

Overall, this granted patent provides protection for a compound and its pharmaceutically acceptable forms, as well as a pharmaceutical composition containing the compound. The claims encompass different substitution options for specific groups in the compound's structure, allowing for potential variations in its properties and applications.

To know more about GlobalData’s detailed insights on Kinnate Biopharma, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies